相关实验视频
Updated: May 8, 2025

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
9.6K
通过整合编程细胞死亡模式和液体活检,揭示较少定义的亚型扩散大B细胞淋巴瘤患者治疗耐药性的异质性
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China.
Clinical and translational medicine
|December 28, 2024
概括
研究人员使用机器学习开发了一个编程细胞死亡指数 (PCDI),用于预测扩散大B细胞淋巴瘤 (DLBCL) 患者的结果. 该指数有助于为这种具有挑战性的癌症制定个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 免疫学 免疫学 免疫学
背景情况:
- 由于其异质性,分散型大B细胞淋巴瘤 (DLBCL) 在精密医学中提出了挑战.
- 编程细胞死亡 (PCD) 途径对于淋巴瘤的进展和预后至关重要.
研究的目的:
- 在较少定义的DLBCL亚型中确定个性化管理的预后生物标志物.
- 开发一个对患者结果的预测模型.
主要方法:
- 从339名用R-CHOP治疗的DLBCL患者获得的综合多组数据.
- 采用机器学习来识别八个关键PCD相关基因.
- 建立了一个编程细胞死亡指数 (PCDI) 和一个预测性名ogram.
主要成果:
- 已经确定了8个关键基因 (FLT3,SORL1,CD8A,BCL2L1,COL13A1,MPG,DYRK2,CAMK2B) 与PCD相关.
- PCDI与ctDNA负担,MRD状态和免疫特征有显著的相关性.
- 高PCDI得分表明潜在的化学抵抗性,但可能从向抑制剂中获益.
结论:
- 对于较少定义的DLBCL,PCDI作为一个强大的预后生物标志物.
- 开发了一个在线工具,用于预后预测和加强临床管理.
- 结果表明,针对DLBCL患者,基于PCDI的量身定制的治疗策略.
相关概念视频
Combination Therapies and Personalized Medicine
4.7K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.7K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K

